ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) shares were down 3.8% during trading on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares were traded during mid-day trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Stock Performance
The business has a fifty day moving average price of C$6.00. The stock has a market cap of C$51.48 million, a PE ratio of -1.78 and a beta of 1.19. The company has a debt-to-equity ratio of 108.33, a quick ratio of 1.30 and a current ratio of 0.51.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Articles
- Five stocks we like better than ProMIS Neurosciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- High-Yield Texas Instruments Could Hit New Highs Soon
- P/E Ratio Calculation: How to Assess Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Investing In Automotive Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
